Drugs / Edoxaban
Edoxaban
also known as
DU-176b · Lixiana · D006 · edoxaban tosylate · DU-176 · Edoxaban (Savaysa) · Edoxaban tosilate · Roteas · +1 more
Small molecule targets F10 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | SAVAYSA | — | 2019-08-09 – 2023-10-18 | fda.gov ↗ |
| Approved | EU (EMA) | Lixiana | — | 2015-06-19 | europa.eu ↗ |
| Approved | US (FDA) | SAVAYSA | — | 2015-01-08 | fda.gov ↗ |
Trials 86 · started per year
today
US approved 2015
EU approved 2015
1
2
3
3
3
1
2
3
3
2
3
13
8
12
3
4
5
4
6
3
2
200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07113054 | Sep 2025 overdue | — | Hyewon Chung | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06326138 | Mar 2024 | — | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Withdrawn | No outcome recorded |
| Phase 1 | NCT06372483 | Feb → Aug 2024 overdue | blood coagulation disease | VarmX B.V. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05723510 | Mar → Jul 2023 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04867200 | Apr → May 2021 | — | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04673695 | Nov → Dec 2020 | — | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT02303431 | Nov 2014 → Sep 2021 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02047565 | Oct 2013 → May 2014 | hemorrhagic disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT05869591 | Jan 2024 → Jun 2026 overdue | cirrhosis of liver | Centre Hospitalier Universitaire Vaudois | Recruiting | No outcome recorded |
| Phase 2 | NCT05006287 | Oct 2022 → May 2024 | atrial fibrillation | St. Paul's Hospital, Canada | Unknown | No outcome recorded |
| Phase 2 | NCT05540587 | May 2022 → May 2024 | atrial fibrillation, mitral valve stenosis, stroke disorder | Sung-Hwan Kim | Unknown | No outcome recorded |
| Phase 2 | NCT03433235 | Jun 2018 → Apr 2020 | ischemic stroke | Jong Sung Kim | Completed | No outcome recorded |
| Phase 2 | NCT03489395 | Jan 2018 → Dec 2020 | atrial fibrillation | Raffaele De Caterina | Completed | No outcome recorded |
| Phase 2 | NCT03310021 | Aug 2017 → Aug 2019 | hemorrhagic disease | Portola Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02998905 | Apr 2017 → Oct 2019 | atrial fibrillation, intracerebral hemorrhage | Population Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02207257 | Mar 2014 → Sep 2015 | — | AMAG Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01802775 | Feb 2013 → Dec 2014 | peripheral arterial disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01662908 | Aug 2012 → Jan 2014 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01203098 | Jul → Dec 2008 | osteoarthritis, hip, thrombotic disease, venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00806624 | Oct 2007 → Oct 2008 | atrial fibrillation, stroke disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00504556 | Jun 2007 → Jun 2008 | atrial fibrillation, thrombotic disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00829933 | Mar 2007 → Jul 2008 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01203072 | Jul 2006 → Sep 2007 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00398216 | May 2006 → Jun 2007 | thrombotic disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00107900 | Jan → Dec 2005 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05122455 | Sep 2021 → Jun 2024 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT03570281 | Jun 2018 → May 2020 | — | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2/3 | NCT02221102 | Dec 2013 → Jun 2015 | cerebral infarction, ischemic disease | Xijing Hospital | Unknown | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT07454707 | Apr 2026 → Dec 2031 expected | ischemic stroke | Sunnybrook Health Sciences Centre | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06149533 | Nov 2023 → May 2026 overdue | cancer, venous thromboembolism | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05035277 | Dec 2021 → Jun 2026 | aortic valve stenosis | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04542408 | Nov 2020 → Sep 2022 | COVID-19 | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 3 | NCT04045665 | Dec 2019 → Aug 2026 overdue | atrial fibrillation, hemorrhagic disease, stroke disorder | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 3 | NCT03961334 | Dec 2019 → Jan 2025 | ischemic stroke | University of Zurich | Unknown | No outcome recorded |
| Phase 3 | NCT04171726 | Aug 2019 → Jun 2023 | aortic valve stenosis | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03996772 | Jun 2019 → May 2024 | atrial fibrillation, intracerebral hemorrhage | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT03395639 | May 2018 → Dec 2021 | heart disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT03153150 | Mar 2018 → Mar 2021 | atrial fibrillation, atrial flutter, intracerebral hemorrhage, subarachnoid hemorrhage | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT03244319 | Dec 2017 → Sep 2019 | cardiac valvular defect | Yonsei University | Completed | No outcome recorded |
| Phase 3 | NCT02798471 | Mar 2017 → May 2022 | pulmonary embolism, venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02942576 | Mar 2017 → Sep 2018 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02943785 | Mar 2017 → Feb 2021 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02866175 | Feb 2017 → Jun 2019 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02801669 | Aug 2016 → Dec 2019 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02618577 | Feb 2016 → Dec 2022 | atrial tachycardia | Atrial Fibrillation Network | Terminated | No outcome recorded |
| Phase 3 | NCT02073682 | Jul 2015 → Sep 2017 | cancer, pulmonary embolism, venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02072434 | Mar 2014 → Feb 2016 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01857583 | Mar → Dec 2012 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01857622 | Nov 2011 → Jan 2013 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00986154 | Oct 2009 → Apr 2013 | pulmonary embolism, thrombotic disease, venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01181167 | May 2009 → Jan 2010 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01181102 | Mar → Sep 2009 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00781391 | Nov 2008 → Apr 2013 | atrial fibrillation, stroke disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01181141 | Oct 2008 → Aug 2009 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT07609654 | Jun 2026 → Jun 2029 expected | atrial fibrillation, intracerebral hemorrhage, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06402851 | Dec 2024 → Dec 2026 expected | atrial fibrillation, chronic kidney disease | Hospital Sirio-Libanes | Recruiting | No outcome recorded |
| Phase 4 | NCT06401616 | May 2024 → Mar 2028 expected | atrial fibrillation | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04436978 | Jan 2023 → Oct 2027 expected | ST-elevation myocardial infarction, acute coronary syndrome, atrial fibrillation, atrial flutter +3 | St. Antonius Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05320627 | Mar 2022 → Aug 2024 | atrial fibrillation | China National Center for Cardiovascular Diseases | Completed | No outcome recorded |
| Phase 4 | NCT05292846 | Jan 2022 → Feb 2024 | coronary artery disorder, hemorrhagic disease | Hospital Universitario La Fe | Unknown | No outcome recorded |
| Phase 4 | NCT04700826 | Jun 2021 → Dec 2027 expected | atrial fibrillation | University of Birmingham | Recruiting | No outcome recorded |
| Phase 4 | NCT03950076 | Sep 2019 → May 2026 overdue | atrial fibrillation, intracerebral hemorrhage | Population Health Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04072068 | Jun 2019 → Mar 2022 | cancer, venous thromboembolism | Italian Oncology Group for Clinical Research | Completed | No outcome recorded |
| Phase 4 | NCT03968393 | Jun 2019 → Dec 2028 expected | atrial fibrillation, stroke disorder | Population Health Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT03895502 | May 2019 → Jun 2023 | cancer or benign tumor, venous thromboembolism | Takeshi Morimoto | Completed | No outcome recorded |
| Phase 4 | NCT03840291 | May 2019 → Oct 2023 | atrial fibrillation | Keimyung University Dongsan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03718559 | May 2019 → Nov 2023 | atrial fibrillation, intermediate coronary syndrome | Gi-Byoung Nam | Completed | No outcome recorded |
| Phase 4 | NCT03666650 | Nov 2018 → Jan 2019 | blood coagulation disease | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03494530 | Jun 2018 → Dec 2021 | atrial fibrillation, hemorrhagic stroke, ischemic stroke | University of Alberta | Completed | No outcome recorded |
| Phase 4 | NCT03284827 | Mar 2018 → Oct 2021 | aortic valve stenosis | Duk-Woo Park, MD | Completed | No outcome recorded |
| Phase 4 | NCT03088072 | Mar 2017 → Nov 2018 | atrial fibrillation | Scripps Health | Unknown | No outcome recorded |
| Phase 4 | NCT03073850 | Feb 2017 → Dec 2019 | atrial fibrillation | Korea University Guro Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02666742 | Feb 2017 → May 2020 | stroke disorder, ventricular tachycardia | Kansas City Heart Rhythm Institute | Completed | No outcome recorded |
| Phase 4 | NCT02567461 | Mar 2016 → Oct 2017 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02561897 | Dec 2015 → Sep 2017 | atrial fibrillation | Electrophysiology Research Foundation | Terminated | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07116239 | Sep 2025 → Feb 2026 overdue | nephrotic syndrome | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06864052 | Mar 2025 → Sep 2029 expected | atrial fibrillation, ischemic stroke | Ewha Womans University Seoul Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06285942 | Feb 2024 → Jan 2025 | atrial fibrillation | Azienda Ospedaliero Universitaria Maggiore della Carita | Unknown | No outcome recorded |
| — | NCT06057467 | Sep 2023 → Oct 2025 | atrial fibrillation, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05419583 | Nov 2022 → Jun 2024 | myocardial infarction | University of Edinburgh | Completed | No outcome recorded |
| — | NCT05801068 | Aug 2020 → May 2024 overdue | atrial fibrillation, hemorrhagic disease | Seoul National University Hospital | Active not recruiting | No outcome recorded |
| — | NCT03759938 | Jun 2019 → May 2024 | atrial fibrillation, ischemic stroke | University College, London | Unknown | No outcome recorded |
| — | NCT03642509 | Jan 2019 → Jan 2026 overdue | atrial fibrillation, stroke disorder | University of Aarhus | Recruiting | No outcome recorded |
| — | NCT04121767 | Dec 2017 → Jun 2020 | atrial fibrillation, blood coagulation disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT03148457 | Nov 2017 → Dec 2022 | ischemic stroke | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| — | NCT02964949 | Jan 2017 → Oct 2018 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
Also used as a comparator or background therapy in 30 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05491460 Comparator | Jul 2022 → Dec 2023 | — | Doasense GmbH | Unknown | No outcome recorded |
| Phase 1 | NCT05152420 Background | Oct 2021 → Feb 2023 | blood coagulation disease | VarmX B.V. | Completed | No outcome recorded |
| Phase 1 | NCT03083704 Background | Feb → Sep 2017 | hemorrhagic disease | Portola Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04002011 Comparator | Mar 2022 → Jan 2023 | bleeding disorder, vascular-type | Laval University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02339415 Comparator | Jul 2015 → Sep 2018 | HIV infectious disease, blood coagulation disease | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03551743 Background | Dec 2012 → Sep 2015 | — | Portola Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06900725 Comparator | Apr 2025 → Dec 2030 expected | atrial fibrillation, ischemic stroke | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06322953 Comparator | Mar 2025 → Dec 2027 expected | traumatic brain injury | Walton Centre NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 3 | NCT04284839 Comparator | Jul 2021 → Jun 2027 expected | — | Population Health Research Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT04730037 Comparator | Mar 2021 → Mar 2023 | chronic thromboembolic pulmonary hypertension | Kyushu University | Completed | No outcome recorded |
| Phase 3 | NCT04516941 Comparator | Jan 2021 → Aug 2022 | COVID-19 | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 3 | NCT01924065 Comparator | Aug 2013 → Aug 2017 | atrial fibrillation, stroke disorder | Suleyman Demirel University | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06650501 Comparator | Jan 2026 → Jan 2030 expected | infective endocarditis, staphylococcal toxemia, staphylococcus aureus infection | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 4 | NCT03129555 Comparator | Apr 2023 → Mar 2027 expected | pulmonary embolism, venous thromboembolism | Herlev and Gentofte Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03129490 Comparator | Apr 2023 → Oct 2027 expected | atrial fibrillation, atrial flutter | Herlev and Gentofte Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03568890 Comparator | Sep 2018 → Aug 2025 overdue | hemorrhagic disease, thrombotic disease, transient ischemic attack | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03463317 Comparator | Feb 2018 → Nov 2024 | atrial fibrillation | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02735902 Background | Jun 2017 → Feb 2023 | — | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03062319 Comparator | Apr 2017 → Jul 2023 | atherosclerosis, atrial fibrillation, ischemic stroke | National Hospital Organization Osaka National Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02935855 Comparator | Sep 2015 → Apr 2019 | diabetes mellitus | University of Pavia | Completed | No outcome recorded |
| Phase 4 | NCT01962545 Background | Nov 2013 → May 2017 | atrial fibrillation, coronary artery disorder | Satoshi Shizuta | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07497893 Background | Dec 2026 → Nov 2029 expected | atrial fibrillation | Ewha Womans University Mokdong Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07583784 Comparator | Jul 2026 → Dec 2031 expected | ST-elevation myocardial infarction, atrial fibrillation | Chonnam National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07616414 Comparator | May → Dec 2026 expected | atrial fibrillation, thrombotic disease | Fu Wai Hospital, Beijing, China | Not yet recruiting | No outcome recorded |
| — | NCT04684212 Comparator | Jun 2024 | atrial fibrillation, stroke disorder | Brian O'Neill MD | Withdrawn | No outcome recorded |
| — | NCT05472766 Comparator | Nov 2022 → Mar 2024 | atrial fibrillation | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| — | NCT06449469 Background | May 2021 → Apr 2026 overdue | aortic valve stenosis | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT03465735 Background | Jan 2017 → Aug 2019 | venous thromboembolism | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT02744092 Comparator | Dec 2016 → Oct 2020 | cancer, pulmonary embolism, thrombotic disease, venous thromboembolism | Alliance Foundation Trials, LLC. | Completed | No outcome recorded |
| — | NCT01999179 Background | Jun 2014 → Apr 2019 | neoplasm, venous thromboembolism | Medical College of Wisconsin | Completed | No outcome recorded |
Press releases naming this drug 48 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-09-11 | Daiichi Sankyo | Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes in Usage or Dosage for Anticoagulant Edoxaban daiichisankyo.com ↗ |
| 2020-08-31 | Daiichi Sankyo | Daiichi Sankyo Announces Results of Phase 3 Clinical Trial for Anticoagulant Edoxaban (ELDERCARE-AF Study) daiichisankyo.com ↗ |
| 2019-09-04 | Daiichi Sankyo | Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation daiichisankyo.com ↗ |
| 2019-03-19 | Daiichi Sankyo | Daiichi Sankyo Presents Positive Results of the First Randomized, Controlled Trial of Uninterrupted Oral, Once-daily Lixiana® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation daiichisankyo.com ↗ |
| 2017-12-13 | Daiichi Sankyo | Once-Daily, Oral LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study daiichisankyo.com ↗ |
| 2017-11-29 | Daiichi Sankyo | Daiichi Sankyo Launches Anticoagulant LixianaⓇ OD Tablets (orally disintegrating tablets) in Japan daiichisankyo.com ↗ |
| 2017-11-15 | Daiichi Sankyo | New LIXIANA® sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017 daiichisankyo.com ↗ |
| 2017-05-08 | Daiichi Sankyo | Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation daiichisankyo.com ↗ |
| 2017-03-31 | Daiichi Sankyo | Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation daiichisankyo.com ↗ |
| 2017-03-07 | Daiichi Sankyo | Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily Lixiana® (edoxaban) in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stenting daiichisankyo.com ↗ |
| 2016-08-30 | Daiichi Sankyo | ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo’s Once-Daily LIXIANA® in Patients with Atrial Fibrillation Undergoing Cardioversion daiichisankyo.com ↗ |
| 2016-08-24 | Daiichi Sankyo | Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban daiichisankyo.com ↗ |
| 2016-06-27 | Daiichi Sankyo | Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban daiichisankyo.com ↗ |
| 2016-02-17 | Daiichi Sankyo | Daiichi Sankyo Launches Once-Daily LIXIANAⓇ Sales Alliance in Europe daiichisankyo.com ↗ |
| 2015-12-28 | Daiichi Sankyo | Daiichi Sankyo Korea Signs Agreement with Daewoong Pharmaceutical for the Co-promotion of LIXIANA® in South Korea daiichisankyo.com ↗ |
| 2015-09-24 | Daiichi Sankyo | UK’s NICE recommends once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation daiichisankyo.com ↗ |
| 2015-08-26 | Daiichi Sankyo | UK’s NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults daiichisankyo.com ↗ |
| 2015-06-25 | Daiichi Sankyo | Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE daiichisankyo.com ↗ |
| 2015-06-19 | Daiichi Sankyo | Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer daiichisankyo.com ↗ |
| 2015-04-27 | Daiichi Sankyo | Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe daiichisankyo.com ↗ |
| 2015-04-15 | Daiichi Sankyo | Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland daiichisankyo.com ↗ |
| 2015-02-09 | Daiichi Sankyo | SAVAYSA™ (edoxaban) Now Available in U.S. Pharmacies daiichisankyo.com ↗ |
| 2015-01-09 | Daiichi Sankyo | U.S. FDA Approves Daiichi Sankyo’s Once-Daily SAVAYSA™ (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism daiichisankyo.com ↗ |
| 2014-12-08 | Daiichi Sankyo | Daiichi Sankyo Launches New Formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan daiichisankyo.com ↗ |
| 2014-10-31 | Daiichi Sankyo | U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA™ (edoxaban) for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation daiichisankyo.com ↗ |
| 2014-09-26 | Daiichi Sankyo | Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan daiichisankyo.com ↗ |
| 2014-09-03 | Daiichi Sankyo | Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes daiichisankyo.com ↗ |
| 2014-04-01 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion daiichisankyo.com ↗ |
| 2014-03-24 | Daiichi Sankyo | Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant daiichisankyo.com ↗ |
| 2014-01-09 | Daiichi Sankyo | Daiichi Sankyo Submits SAVAYSA(TM) (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism daiichisankyo.com ↗ |
| 2014-01-08 | Daiichi Sankyo | Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism daiichisankyo.com ↗ |
| 2013-12-19 | Daiichi Sankyo | Daiichi Sankyo Submits Supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for New Indications daiichisankyo.com ↗ |
| 2013-12-10 | Daiichi Sankyo | Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer daiichisankyo.com ↗ |
| 2013-11-20 | Daiichi Sankyo | Daiichi Sankyo´s Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial daiichisankyo.com ↗ |
| 2013-09-01 | Daiichi Sankyo | Daiichi Sankyo’s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence daiichisankyo.com ↗ |
| 2013-04-26 | Daiichi Sankyo | Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban daiichisankyo.com ↗ |
| 2012-10-25 | Daiichi Sankyo | Daiichi Sankyo Completes Enrolment in Hokusai-VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE daiichisankyo.com ↗ |
| 2011-12-13 | Daiichi Sankyo | Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery daiichisankyo.com ↗ |
| 2011-07-19 | Daiichi Sankyo | Daiichi Sankyo Launches LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery daiichisankyo.com ↗ |
| 2011-04-22 | Daiichi Sankyo | Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (Edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery daiichisankyo.com ↗ |
| 2010-12-08 | Daiichi Sankyo | EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL HIP REPLACEMENT daiichisankyo.com ↗ |
| 2010-12-02 | Daiichi Sankyo | DAIICHI SANKYO COMPLETES ENROLLMENT OF THE EDOXABAN GLOBAL PHASE 3 ENGAGE AF-TIMI 48 STUDY IN PATIENTS WITH ATRIAL FIBRILLATION daiichisankyo.com ↗ |
| 2010-07-12 | Daiichi Sankyo | EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL KNEE REPLACEMENT daiichisankyo.com ↗ |
| 2010-04-06 | Daiichi Sankyo | DAIICHI SANKYO SUBMITS FIRST NEW DRUG APPLICATION FOR ORAL FACTOR Xa INHIBITOR, EDOXABAN daiichisankyo.com ↗ |
| 2009-12-11 | Daiichi Sankyo | Results of a Clinical Phase 3 Trial of an Oral Factor Xa Inhibitor, Edoxaban, in Prevention of Post-Operative Venous Thromboembolism daiichisankyo.com ↗ |
| 2009-07-16 | Daiichi Sankyo | ANALYSIS OF EDOXABAN PHASE II DATA PROVIDES INSIGHT INTO REDUCED BLEEDING EVENTS SEEN IN ONCE-DAILY DOSING daiichisankyo.com ↗ |
| 2008-12-08 | Daiichi Sankyo | NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION daiichisankyo.com ↗ |
| 2008-09-02 | Daiichi Sankyo | Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b daiichisankyo.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 117 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | edoxaban | “DOACs (eg Apixaban, dabigatran, edoxaban and rivaroxaban) are recommended by The National Institute for Health and Care Excellence (NICE) for those over 65 with AF and a...” NCT06322953 ↗104“NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice...” NCT01962545 ↗ “edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or...” NCT03968393 ↗ “Non-vitamin K antagonist oral anticoagulant therapy (e.g., apixaban, rivaroxaban, dabigatran, or edoxaban) administered according to approved labeling and guideline-recommended dosing.” NCT07497893 ↗ “Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.” NCT07583784 ↗ “Patients who are over 20 years old, have non-valvular atrial fibrillation, and are taking rivaroxaban, apixaban, or edoxaban (active ingredients)” NCT05801068 ↗ “NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily.” NCT04436978 ↗ “Administration of approved DOACs (e.g., apixaban, rivaroxaban, edoxaban, or dabigatran) at standard stroke prevention dosages.” NCT07609654 ↗ “Oral factor Xa inhibitors (oral FXaI, eg, apixaban, edoxaban or rivaroxaban) are commonly prescribed for this indication.” PMID 41387009 ↗ Dec 2025 “For edoxaban: 15mg once daily for patients with standard 30mg dose, 30mg once daily for patients with standard 60mg dose” NCT07616414 ↗ “Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation.” NCT02998905 ↗ “Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.” NCT06402851 ↗ “Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.” NCT03642509 ↗ “The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg” NCT02735902 ↗ “choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice” NCT04700826 ↗ “Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP” NCT05472766 ↗ “any approved direct oral anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran)” NCT04045665 ↗ “direct oral anticoagulant treatment (apixaban, rivaroxaban, dabigatran, or edoxaban)” NCT01999179 ↗ “Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.” NCT06057467 ↗ “comparing edoxaban with dual antiplatelet therapy (aspirin plus clopidogrel)” PMID 35373583 ↗ Apr 2022 “Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban” NCT06401616 ↗ “Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)” NCT05006287 ↗ “warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage” NCT01924065 ↗ “warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban” NCT03062319 ↗ “dabigatran, apixaban, edoxaban, rivaroxaban” NCT03759938 ↗ “Apixaban Dabigatran Edoxaban Rivaroxaban” NCT05292846 ↗ “Edoxaban (Savaysa)” NCT03465735 ↗ “Edoxaban of 30mg” NCT03073850 ↗ “Edoxaban” NCT02666742 ↗ |
| Known as | D006 | “Drug: Lixiana(D006)” NCT04867200 ↗1“Drug: Lixiana(D006)” NCT04673695 ↗ |
| Known as | DU-176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1269025 ↗ |
| Known as | DU-176b | “edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment” NCT01662908 ↗12“edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment” NCT00986154 ↗ “A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery” NCT00398216 ↗ “Drug: Edoxaban (DU-176b)” NCT00504556 ↗ |
| Known as | Edoxaban (Savaysa) | “Edoxaban (Savaysa)” NCT03465735 ↗ |
| Known as | Edoxaban tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1269025 ↗ |
| Known as | edoxaban tosylate | “edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment” NCT01662908 ↗1“edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment” NCT00986154 ↗ |
| Known as | Lixiana | “Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)” NCT03148457 ↗ |
| Known as | Roteas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1269025 ↗ |
| Known as | Savaysa | “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗ |
| Action | Inhibit | “Coagulation factor X inhibitor” CHEMBL1269025 ↗1“Factor Xa inhibitor” NCT00398216 ↗ |
| Modality | Small molecule | — CHEMBL1269025 ↗ |
| Route | Oral | “Oral DU-176b” NCT00107900 ↗ |
| Target | F10 | “Coagulation factor X inhibitor” CHEMBL1269025 ↗ |